We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers engaging in anticompetitive practices don’t get a free pass simply because federal regulators failed to act, the Federal Trade Commission has asserted in a pending court case. Read More
Allergan is taking its dispute with the state of New York over mandatory access to an older medication amid generic substitution all the way to the Supreme Court. Read More
A federal court has placed a temporary sales ban on Indian drugmaker Dr. Reddy’s Laboratories’ generic form of heartburn drug Nexium in the U.S. Read More
The majority of the Senate Committee on Health, Education, Labor and Pensions, from both sides of the aisle, supported Robert Califf’s nomination as the next FDA commissioner during a two-hour confirmation hearing Nov. 17. Read More
Biosimilars experts concluded that fostering the nascent industry would require many of the same elements that originally nurtured the generics industry: educational efforts, regulatory and patent changes, and most importantly, patience. Read More
Pfizer and Allergan announced Monday they have struck an agreement on their rumored merger, joining forces in a massive $160 billion deal that would create the world’s largest drugmaker and combine brand names such as Botox, Lipitor and Viagra. Read More